CONGRESS MATERIALS

Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

I am a Healthcare Professional in the HKSARYes, I am a healthcare professional
SelectI am a Healthcare Professional in the HKSARYes, I am a healthcare professional
I am NOT a Healthcare ProfessionalNo, go back to the patient portal
SelectI am NOT a Healthcare ProfessionalNo, go back to the patient portal

I am a healthcare professional in another country

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Oral Presentation
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaci D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B October 2, 2021 EADV 2021 Vitiligo

Efficacy and safety of the oral Janus kinase 3/TEC inhibitor ritlecitinib (PF-06651600) in adults with active non-segmental vitiligo: results from a phase 2b, randomized, dose-ranging study with an extension period

View Presentation
Poster
Kitchen H, Wyrwich KW, Johnson C, Deal LS, Lukic T, Gandhi K, Al-Zubeidi T, Marshall C, Pegram H, Hamzavi IH, King B October 2, 2021 EADV 2021 Vitiligo

Meaningful changes in what matters to patients with vitiligo

View Presentation
Poster
Al Hammadi A, Parmar N, Hatatah N, Ahmed H, Sunna N, Hegazy R October 2, 2021 EADV 2021 Vitiligo

Review of disease burden and unmet need of vitiligo in Africa and Middle East

View Presentation
Oral Presentation
Guttman-Yassky E, Pavel AB, Del Duca E, Correa Da Rosa J, Yamaguchi Y, Ye Z, He W, Hyde C, Hassan-Zahraee M, Peeva E November 6, 2021 ISDS 2021 Vitiligo

Vitiligo Patients Show Significant Changes in Skin and Blood Immune/Melanocytes Biomarkers with Oral JAK3/TEC Inhibitor Ritlecitinib

View Presentation
Oral Presentation
Peeva E, Yamaguchi Y, King B, Han G, Cox L, Banerjee A, Picardo M, Bae JM, Sloan A, Sinclair R, Ezzedine K March 29, 2022 AAD 2022 Vitiligo

Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active non-segmental vitiligo across Fitzpatrick skin types: results from a Phase 2b, randomized, dose-ranging study with an extension period

View Presentation
Oral Presentation
Yamaguchi Y, Peeva E, Shore R, Han G, Cox LA, Banerjee A, Thaci D, Hamzavi I, Sloan A, Ganesan AK, Ezzedine K March 29, 2022 AAD 2022 Vitiligo

Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes re-pigmentation of stable lesions in patients with active non-segmental vitiligo: results from a Phase 2b, randomized, placebo-controlled, dose-ranging study

View Presentation